Etanercept
-
Subject Areas on Research
- A brief history of Wegener's granulomatosis: on limited, localized, and generalized forms of the disease: comment on the article by the Wegener's Granulomatosis Etanercept Trial Research Group.
- A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.
- A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis.
- ADA2 deficiency (DADA2) associated with Evans syndrome and a severe ADA2 genotype.
- Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's).
- Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America.
- Case reports of heart failure after therapy with a tumor necrosis factor antagonist.
- Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors.
- Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs.
- Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).
- Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
- Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks.
- Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis.
- Endogenous tumor necrosis factor alpha (TNFalpha) requires TNF receptor type 2 to generate heat hyperalgesia in a mouse cancer model.
- Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature.
- Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.
- Etanercept plus standard therapy for Wegener's granulomatosis.
- Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis.
- Extension study of participants from the trial of early aggressive therapy in juvenile idiopathic arthritis.
- Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists.
- Herpes zoster in immunocompromised patients: incidence, timing, and risk factors.
- Hodgkin's lymphoma and tumor necrosis factor inhibitors in juvenile idiopathic arthritis.
- Inflammatory Bowel Disease in Children With Systemic Juvenile Idiopathic Arthritis.
- Inflammatory biomarkers in heart failure.
- Juvenile idiopathic arthritis.
- Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis.
- Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets.
- New treatments for rheumatoid arthritis.
- Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's).
- Progress in the treatment of rheumatoid arthritis.
- Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept.
- Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort.
- Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial.
- Sustained stimulation of β2- and β3-adrenergic receptors leads to persistent functional pain and neuroinflammation.
- TNF-α/TNFR1 Signaling is Required for the Full Expression of Acute and Chronic Itch in Mice via Peripheral and Central Mechanisms.
- Targeting pro-inflammatory cytokines following joint injury: acute intra-articular inhibition of interleukin-1 following knee injury prevents post-traumatic arthritis.
- The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis.
- Tides of inflammation: impact of biologics.
- Treatment Strategies for Deficiency of Adenosine Deaminase 2.
- Treatment of juvenile pityriasis rubra pilaris with etanercept.
- Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis.
- Tumor necrosis factor alpha and colitis-associated colon cancer.
- Tumor necrosis factor blockers in rheumatoid arthritis.
- Tumor necrosis factor-alpha antagonism with etanercept improves endothelial progenitor cell counts in patients with psoriasis: etanercept, vascular function and endothelial progenitor cells in psoriasis.
- Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease.
- Tumour necrosis factor-alpha blockade: a new era for effective management of rheumatoid arthritis.
- Warts and DADA2: a Mere Coincidence?